
|Videos|October 23, 2017
Dr. Geynisman Discusses Immunotherapy in RCC
Author(s)Daniel M. Geynisman, MD
Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma.
Advertisement
Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma (mRCC).
Patients are excited and willing to participate in clinical trials of immunotherapy, says Geynisman. In RCC, select patients have shown to derive benefit from immunotherapy.
Geynisman says that trials of immunotherapy and targeted therapies will undoubtedly change the treatment paradigm in mRCC.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5



































